Azatadine

Oral
Allergic conditions

May be taken with or without food. May be taken w/ food or milk if stomach upset occurs.

Neonates; patients receiving MAOI therapy; lactation.

Angle-closure glaucoma, increased intraocular pressure, stenosing peptic ulcer, pyloroduodenal obstruction, epilepsy; renal and hepatic impairment. May impair ability to drive or operate machinery; pregnancy.

Drowsiness, dizziness, headache, fatigue, nervousness; anticholinergic effects, thick bronchial secretions; arthralgia; pharyngitis; increased appetite, wt gain, nausea, diarrhoea, abdominal pain, dry mouth; impaired alertness.

Potentiates CNS depression with other CNS depressants e.g. TCAs, procarbazine and alcohol.
Potentially Fatal: MAOIs enhance anticholinergic side effect of azatadine. Enhance depressant action of anxiolytic and sedating drugs.

Alcohol may enhance sedative effects.

Description: Azatadine has anticholinergic and antiserotonin activity. It inhibits mediator release from mast cells by preventing calcium entry through voltage-dependent calcium channels.
Pharmacokinetics:
Absorption: Absorbed from the GI tract (oral); peak plasma concentrations after 4 hr.
Metabolism: Minimal metabolism.
Excretion: Via the urine (as unchanged drug and metabolites); 9-12 hr (elimination half-life).

Store at 2-30°C.

Antihistamines & Antiallergics